Long-term 10-year outcomes study¹

Objective

This study examined the long-term (>10 years) safety and efficacy of Enterra Therapy in patients with intractable nausea and vomiting.

Design

Retrospective, single-centre French study examining 50 consecutive patients with refractory chronic nausea and/or vomiting lasting at least 12 months (failure of 2 prokinetics and antiemetics) implanted with gastric electrical stimulator.

Primary endpoint

• Gastrointestinal Quality of Life Index (GIQLI) score.
• Primary outcome was reduction in nausea and/or vomiting using a 5-point score.
• Reduction in nausea and/or vomiting by 1 point, defined as >50% reduction in frequency.

Results

• In a retrospective study of 50 patients, Enterra Therapy significantly improved primary endpoint of nausea and vomiting in 54% of patients by greater than 50% at 10 years.
• Enterra Therapy significantly improved primary endpoint of Gastrointestinal QOL Index (GIQLI) score and patients reported high level of satisfaction (80%) with the therapy at 10 years.

Nausea

Vomiting

Gastrointestinal quality of life index (GIQLI) score

Median overall GIQLI patient satisfaction score

1. Hedjoudje A, Huet E, Leroi AM, Desprez C, Melchior C, Gourcerol G. Efficacy of gastric electrical stimulation in intractable nausea and vomiting at 10 years: A retrospective analysis of prospectively collected data. Neurogastroenterol Motil. 2020;32(11):e13949. doi:10.1111/nmo.13949.